BioVie completes last patient treatment visit in Phase 3 trial of NE3107

BioVie announced that the last patient has completed the last visit at week 30 in its multicenter, randomized, placebo-controlled Phase 3 study of NE3107 in patients with mild to moderate Alzheimer’s Disease. The Company’s clinical monitors have started the process working with each clinical site to ensure that the electronic data capture database properly reflects the assessments captured during the various clinical visits. This is the critical first step to creating and locking the database for analyzing the trial results and the eventual submission to the FDA for their review. The trial’s Statistical Analysis Plan that pre-specifies the analyses and treatment populations and subgroups will be submitted to the FDA prior to locking the EDC.